User Tools

Site Tools


research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2016/11/14 13:03]
schillil
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2017/10/31 15:43] (current)
maura_beaton
Line 1: Line 1:
- ======Characterization of Oral Antibiotics for Acne Treatment======+=====Characterization of Oral Antibiotics for Acne Treatment======
  
-**Objective:​** ​//  +**Objective:​**  
-We aim to characterize ​1the use of oral antibiotics ​for the treatment of acne in children and adolescents ​and 2)assess guideline compliance ​of current clinical practice around ​the world.//+Aim 1: Characterize ​the international distribution ​of oral antibiotic use for acne in the pediatric ​and young adult population ages 12 to 21. 
 +Aim 2: Characterize the international distribution ​of oral antibiotic use for acne in the adult population ages 22 to 60.
  
-**Rationale:​** //Acne is a common and disabling medical ​problemespecially among adolescents.[1] Guidelines established by the American Academy of Dermatology ​(AAD) recommend ​to minimize ​the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1] A recent systematic review demonstrated that over 50% of P acnes strains are reported as resistant in all major regions of the world.[2] In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, ​and possible associations with inflammatory bowel disease and obesity.[3] Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[3] A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[3] OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance.//​+//**Rationale:​** // 
 +Acne is a common and disabling medical ​conditionparticularly amongst ​adolescents ​and young adults.[1]  ​According to the Global Burden of Disease Study 2016, acne is the most disabling skin condition worldwide, responsible for 0.28% of global burden from all diseases.[2] ​ In addition to physical disfigurement,​ the profound psychosocial effects of acne have been recognized for over half a century.[3]  ​Guidelines established by the American Academy of Dermatology recommend ​minimizing ​the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1] ​ A recent systematic review demonstrated that over 50% of Pacnes strains are reported as resistant in all major regions of the world.[4 In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, ​as well as possible associations with inflammatory bowel disease and obesity.[5 Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[5 A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[5 A similar retrospective cohort study of teenagers and young adults in the US found that 18% of antibiotic courses exceeded 6 months.[6] ​ Our study will investigate oral antibiotic use for acne over the last ten years across the globe in both pediatric/​young adult and adult populations.  ​OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance//.//
  
-**Project Lead(s):** //Stephanie Chapman, Renee Domozych, Jessica Mounessa, Jonathan Silverberg, David Barbieri, Robert P. Dellavalle, Lisa M. Schilling//+**Project Lead(s):​** ​ //Chante Karimkhani, Robert P. Dellavalle, Lisa M. Schilling//
  
-**Full Draft Protocol:** {{research:​acne:​acne_abx_characterization_protocol.docx}}+**Coordinating Institution(s):** //​University of Colorado School of Medicine//
  
 +**Additional Participants:​** // //
  
 +**Full Draft Protocol:** //Please provide any comments or suggestions.//​
 +[[https://​docs.google.com/​document/​d/​1baPHccNGfQtUNEY-bzIqTGGz7E8zbMBS_62nKDI8kGo/​edit#​]]
  
 +**Initial Proposal Date:** //25 August 2016//
  
-  +**Launch Date:​** ​//  //
-//Please provide any comments or suggestions.//+
  
-===== Forum Discussion Thread ​=====  +**Study Closure Date:** // // 
-[[http://​forums.ohdsi.org/​t/​ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/​1703]]// + 
 +**Forum Discussion Thread** 
 + 
 +http://​forums.ohdsi.org/​t/​ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/​1703
  
research/concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris.txt · Last modified: 2017/10/31 15:43 by maura_beaton